<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20100318110343+01'00'</creation_date><modification_date>D:20100318110346+01'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-03-269_h_a_dec_4.pdf</pdf_file></head><body><section><header>en  
   en</header></section><section><header>en</header></section><section><header>en  
   en</header><p>european commission</p><p>brussels, 15.3.2010 c(2010)1767</p></section><section><header>commission decision of 15.3.2010 
 amending the marketing authorisation for &quot;faslodex - fulvestrant&quot;, a medicinal 
 product for human use, granted by decision c(2004)851 
 (only the english text is authentic)</header></section><section><header>en</header><p>2</p></section><section><header>en</header></section><section><header>commission decision of 15.3.2010 
 amending the marketing authorisation for &quot;faslodex - fulvestrant&quot;, a medicinal 
 product for human use, granted by decision c(2004)851 
 (text with eea relevance)</header><p>the european commission, having regard to the treaty on the functioning of the european union, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a 
 european medicines agency
 1, having regard to commission regulation (ec) no 1085/2003 of 3 june 2003 concerning 
 the examination of variations to the terms of a marketing authorisation for medicinal 
 products for human use and veterinary medicinal products falling within the scope of 
 council regulation (eec) no 2309/93
 2, and in particular the first subparagraph of article 6(10) thereof, 
 having regard to the application submitted by astrazeneca uk limited on 22 november 
 2009 under article 6(1) of commission regulation (ec) no 1085/2003, 
 having regard to the opinion of the european medicines agency, formulated by the 
 committee for medicinal products for human use on 20 january 2010, 
 whereas: 
 (1)</p><p>an examination of the major variation type ii to the terms of the marketing 
 authorisation for the medicinal product &quot;faslodex - fulvestrant&quot;, which is entered 
 in the community register of medicinal products under number(s) 
 eu/1/03/269/001 and the placing on the market of which was authorised by 
 decision c(2004)851 of 10 march 2004, has shown that the product remains in 
 compliance with the requirements set out in directive 2001/83/ec of the 
 european parliament and of the council of 6 november 2001 on the community 
 code relating to medicinal products for human use
 3. (2)</p><p>it is therefore appropriate to accept the application(s) in respect of (a) major 
 variation(s) to the terms of the marketing authorisation and to amend decision 
 c(2004)851 accordingly.</p><p>
 1 oj l 136, 30.4.2004, p. 1. 2 oj l 159, 27.6.2003, p. 24. 3 oj l 311, 28.11.2001, p. 67.</p></section><section><header>en</header><p>3</p></section><section><header>en</header><p>has adopted this decision: article 1 decision c(2004)851 is amended as follows: 1) annex i is replaced by the text set out in annex i to this decision; 
 2) annex ii is replaced by the text set out in annex ii to this decision; 
 3) annex iii is replaced by the text set out in annex iii to this decision. 
 article 2 this decision is addressed to astrazeneca uk limited, alderley park, macclesfield, cheshire, sk10 4tg united kingdom. 
 done at brussels, 15.3.2010 
 for the commission robert madelin 
 director-general</p></section></body></xml>